CALGB 70604 (Alliance): A Randomized Phase III Study of Standard Dosing vs. Longer Interval Dosing of Zoledronic Acid in Metastatic Cancer

Comentários

Postar um comentário

Postagens mais visitadas deste blog

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis

http://www.nature.com/articles/srep06269 Abstract Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR mutation in tissues has obvious limitations. Circulating free DNA (cfDNA) has been reported as an alternative approach for the detection of EGFR mutations. This systematic review and meta-analysis was designed to assess the diagnostic performance of cfDNA, compared with tissues. True-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) values were extracted or calculated for each study. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated. A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall diagnostic performance. 20 eligible studies involving 2012 cases were included in this m...
Leia mais

INIBIDORES DE CICLINA 4/6 RESISTÊNCIA / TRATAMENTO "BEYOND PROGRESSION " , EFETIVIDADE EM SNC (ABEMACICLIB) , PIORES PROGNÓSTICOS NOS PACIENTES COM METÁSTASES HEPÁTICAS

Imagem
INIBIDORES DE CICLINA 4/6     TRATAMENTO "BEYOND PROGRESSION " ,    EFETIVIDADE EM SNC (ABEMACICLIB) , PIORES PROGNÓSTICOS NOS PACIENTES COM METÁSTASES HEPÁTICAS ,  MECANISMOS DE RESISTÊNCIA  ‒ ( RB1 mutations were subclonal / New ESR1 and PIK3CA driver mutations acquired on both arms/    ESR1 Y537S selected by fulvestrant )
Leia mais

A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108)

Imagem
Na duvida postei primeiro o comentário da Julie white ,  sobre Seema Khan , fica Realmente a questão sera que não vale a pena operar pacientes com Doença metastática De Novo, deixarei algumas urls, do Pubmed para discussão : Tosello G, Torloni MR, Mota BS, Neeman T, Riera R. Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev. 2018;3(3):CD011276. Published 2018 Mar 15. doi:10.1002/14651858.CD011276.pub2 Thomas A, Khan SA, Chrischilles EA, Schroeder MC. Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011. JAMA Surg. 2016;151(5):424‐431. doi:10.1001/jamasurg.2015.4539 Lane WO, Thomas SM, Blitzblau RC, et al. Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis. Ann Surg. 2019;269(3):537‐544. doi:10.1097/SLA.0000000000002621 Xiong Z, Deng G, Wang J, et al. Could local surgery improve survival in de novo stage IV breast cancer?....
Leia mais